Compare Li Auto Inc (LI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Repligen Corporation Common Stock — how do they compare? Li Auto Inc trades at $11.3 (market cap $11.28B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Li Auto Inc and Repligen Corporation Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 102 Days and Repligen Corporation Common Stock for 0 Days on average.
| LI | RGEN | |
|---|---|---|
Market Cap | $11.28B | $11.31B |
Volume | 2,730,590 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.72 | $194.57 |
52-Week Low | $10.69 | $102.87 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $686.98M | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.75, up 3.07% today but near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with mixed analyst sentiment (43.75% buy, 50% hold). Recent Q2 2026 results missed expectations with a net loss, though vehicle margins improved to 9.4%. New model launches (Li i9, MEGA) and global expansion plans contrast with cash burn concerns, with operating cash flow negative $8.6B in 2025.
Outlook remains challenged by intense EV competition and China's auto market slowdown, but the company's strong balance sheet ($112.8B cash) provides cushion. Analyst consensus target of $15.18 suggests 29% upside if execution improves, though near-term risks from volume pressure and margin compression persist. The stock offers value at 0.78 P/S but requires monitoring of delivery trends and cost controls.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
